RxDoctor Payments Data

Daniel Chadwick, MD

Family Medicine · Crowley, TXNPI 1508828245

Payments from drug & device makers

$11,957in general payments, 2019–2025

Across 734 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$798
  • GSK$749
  • Boehringer Ingelheim$736
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,926100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,957 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,678
Medicare patients
162
Services billed
3,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide213$275,929
OzempicSemaglutide139$213,359
Synjardy XrEmpagliflozin/Metformin Hcl57$92,809
JardianceEmpagliflozin42$72,759
EliquisApixaban35$44,714
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$37,698
JanuviaSitagliptin Phosphate24$34,268
Janumet XrSitagliptin Phos/Metformin Hcl14$16,324
Breo ElliptaFluticasone/Vilanterol13$9,343
Omeprazole254$5,649
Valsartan205$5,025
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,015
Humalog Kwikpen U-100Insulin Lispro28$4,900
Atorvastatin Calcium547$4,632
PremarinEstrogens, Conjugated15$4,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,332$275,929213 claims
Novo NordiskOzempic$1,834$213,359139 claims
Boehringer IngelheimSynjardy Xr, Jardiance$736$165,56899 claims
MerckJanuvia, Janumet Xr$344$50,59238 claims
PfizerEliquis, Premarin$406$49,25650 claims
GSKTrelegy Ellipta, Breo Ellipta$749$47,04140 claims
AbbVieSynthroid$798$1,55930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Crowley

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →